Every week, the same ritual plays out in rheumatology clinics from coast to coast. A physician prescribes a biologic—one of those miraculously targeted drugs that can halt an autoimmune cascade in its tracks. Then comes the waiting. The prescription disappears into what industry insiders grimly call "the prior authorization labyrinth," a bureaucratic maze so byzantine that nearly four in ten requests simply vanish into denial.
The medications themselves? They run upward of $150,000 per patient annually. The human cost of that 37% denial rate is harder to quantify but no less real: delayed treatments, disease progression, clinic staff drowning in paperwork. Hours spent extracting insurer-specific criteria, cross-referencing formularies that shift like sand, filling out forms that somehow manage to be both redundant and maddeningly particular.
Ruma Care thinks it's found a way through. The San Francisco startup—all of two people, announced as part of Y Combinator's Winter 2026 cohort in December 2025—launched an AI-powered platform in January with a pitch stripped of Silicon Valley mysticism: let us extract the right approval criteria, autofill your forms from EHR data, and enroll patients in financial assistance programs. All in one workflow. Early numbers from California and Nevada clinics suggest something might be working. Ruma reports denial rates cut in half, processing times compressed twentyfold.
Whether those numbers hold at scale is the open question. But the ambition alone says something about where healthcare automation is heading.
Biologics, Buy-and-Bill, and the High-Stakes Game
Ruma zeroed in on a narrow but expensive slice of the healthcare economy: infusion centers and specialty practices operating under buy-and-bill reimbursement models. These are your rheumatology clinics, gastroenterology practices, dermatology centers—places that purchase high-cost biologics upfront, administer them to patients, then bill insurers after the fact. A denied claim in this world isn't just paperwork. It's tens of thousands in unrecovered costs, sitting on the clinic's books.
The platform works by pulling patient data from electronic health records, mapping it against insurer-specific prior authorization requirements (which can vary wildly, even within the same insurance company), and auto-populating submission forms. In parallel—and this matters, because it usually runs as a separate headache—it kicks off copay assistance enrollment. Once authorization clears, Ruma monitors reimbursement flows to flag potential denials before they officially land. The company frames this as a learning system, refining its approach based on denial patterns to edge approval rates higher over time.
In January, Ruma also released something it's giving away: the Formulary Navigator, a standalone tool that answers coverage questions by citing actual payer documents. Providers plug in a plan, a medication, a diagnosis. The tool surfaces PA requirements and formulary restrictions. It's a classic top-of-funnel move—offer immediate utility, build trust, let clinics test the waters before committing to the full platform.
The Numbers, With Appropriate Skepticism
Ruma's metrics come from its own deployments, not independent audits. The company says it's cut denial rates by 50% and reduced staff time per prior authorization by a factor of 20 across its early clinic footprint. Y Combinator amplified these claims in a February LinkedIn post, citing 55% fewer denials with the same efficiency gain.
One named customer surfaces on Ruma's site: San Mateo Rheumatology, featured in a testimonial. The company notes it's live "across clinics in California and Nevada" as of January, though no broader customer roster has been made public. For a startup operating with two full-time employees, that footprint suggests either an extremely focused rollout or a platform designed to require minimal hand-holding during onboarding. Perhaps both.
Context makes the denial-reduction claim worth watching. Specialty drug prior authorizations routinely stumble over missing documentation, incorrect coding, or—maddeningly—insurers updating criteria mid-year without fanfare. A June 2024 survey from the American Medical Association found 94% of physicians reporting care delays due to prior authorization, with 95% linking the process directly to burnout. Surescripts, announcing its own automation pilots in October 2025, touted 68% fewer denials due to missing information. The implication? The problem might actually be solvable with better data hygiene and real-time criteria lookup.
Still, Ruma's numbers are early, self-reported, and coming from a company with every incentive to present its best foot forward. The real test will be whether they hold as the clinic base expands and insurer formularies do their annual January shuffle.
Founders With Skin in the Game
Both co-founders carry something beyond the typical startup pitch: personal stakes. CEO Meng Fei Shen, who previously led product work at Uber and Walmart Data Ventures, has a family connection to autoimmune disease. Before launching Ruma, he spent time working as a medical assistant—not a typical move for someone with his resume—specifically to understand clinic workflows from the inside. CTO Christina Huang, who led integrations at Medallion and worked on multimodal experiences at Apple, is herself a long-term biologics patient.
In January, the two co-organized a Biologics Access Symposium with Stanford School of Medicine. It was a positioning move, certainly, but also an indicator they're embedding themselves in the clinical and policy conversation rather than just building from afar.
The technical credentials are solid. Huang's background in health tech integrations and Shen's experience scaling AI tools for Walmart suppliers suggest they understand both the plumbing and the complexity. But—and this is the question that dogs every healthcare automation startup—can a two-person team build enough insurer-specific logic to keep pace with formulary changes and underwriting policies that shift every quarter? Competitors with larger teams and deeper payer relationships have stumbled on exactly that brittleness.
The Market Has a Moment
Specialty medicines hit $417 billion in U.S. sales in 2024, up 12% year-over-year, per IQVIA data published last December. The category now represents more than half of total drug spending. Biologics occupy the high end: $80,000 to $150,000 per patient annually is standard, and some therapies blow past that ceiling. The volume and expense turn prior authorization into a chokepoint with material financial consequences attached.
Timing may be working in Ruma's favor. New federal interoperability rules, finalized in early 2024 under the somewhat bureaucratically named CMS-0057-F, mandate FHIR-based prior authorization APIs for most payers starting January 1, 2027. That deadline is creating urgency on both sides of the equation: payers modernizing digital PA infrastructure, providers hunting for tools to exploit the new data pipes.
Ruma's launch puts it in front of clinics preparing for a more automated workflow landscape. Automated, yes. Simpler? That remains to be seen.
The broader ecosystem is accelerating. Optum announced AI-powered digital prior auth in February, claiming 96% first-pass approvals in recent deployments. CoverMyMeds, owned by McKesson, launched an integrated medication access platform in early March. Surescripts reported in October that its touchless PA network had reached 76,000 prescribers, with a median approval time of 22 seconds for in-scope medications. The infrastructure is coming together. Ruma's bet is there's room for a vertical player laser-focused on buy-and-bill clinic workflows.
A Crowded Field, Narrow Focus
Ruma isn't entering empty territory. The prior authorization automation space is dense with well-funded players. SamaCare, which raised a $17 million Series B in May 2024, processed $6.2 billion in specialty medical-benefit PAs in 2025, according to a February press release. Humata Health pulled in $25 million in mid-2024 from investors including Optum Ventures to expand its generative AI platform. Infinx and AssistRx offer broader PA automation across multiple specialties and payer types, with teams that dwarf Ruma's current headcount.
The differentiation Ruma emphasizes: end-to-end clinic-side automation tailored specifically for infusion workflows. Criteria mapping, form autofill, copay enrollment, reimbursement tracking—all in one system. Incumbents often split those functions across platforms or require manual handoffs between steps. Whether that integration is defensible depends on execution speed and the stickiness of EHR integrations, categories where larger, better-capitalized players typically hold the edge.
The free Formulary Navigator looks like a hedging strategy. It builds visibility and trust without requiring a sales cycle, positioning the company as a resource during the chaotic annual January formulary changes. If clinics adopt the lookup tool, the upsell to the full PA platform becomes a shorter, warmer conversation.
Ruma hasn't disclosed funding beyond Y Combinator's backing. A CB Insights profile lists a $500,000 convertible note, though no matching press release or official announcement confirms that figure. At two employees and a focused product scope, the company's capital efficiency will be tested quickly—especially if scaling requires building out insurer integrations and clinical support infrastructure to match what competitors already have in place.
The Bureaucracy Isn't Going Anywhere
For now, Ruma is live. The early metrics are aggressive, the market opportunity quantifiable. But carving out a durable position against larger automation platforms will hinge on whether the denial reduction holds as the platform scales, and whether infusion clinics value the vertical integration enough to switch away from incumbents.
The prior authorization labyrinth, after all, isn't disappearing—it's just potentially getting faster plumbing. The question isn't whether someone will solve it. The question is who solves it first, and whether a two-person startup can move quickly enough to claim meaningful territory before the giants fully wake up.
Shen and Huang are betting they can. The clinics drowning in paperwork are watching.
